Overcoming Barriers in Oncolytic Virotherapy with HDAC Inhibitors and Immune Checkpoint Blockade
Oncolytic viruses (OVs) target and destroy cancer cells while sparing their normal counterparts. These viruses have been evaluated in numerous studies at both pre-clinical and clinical levels and the recent Food and Drug Administration (FDA) approval of an oncolytic herpesvirus-based treatment raise...
| Main Authors: | , , |
|---|---|
| Format: | Online |
| Language: | English |
| Published: |
MDPI
2016
|
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4728569/ |